Related Experiment Videos
Once daily ceftriaxone for meningococcemia and meningococcal meningitis
1Dr. Sami Ulus Children's Hospital, Department of Pediatric Infectious Diseases, Ankara, Turkey.
Insights
Ceftriaxone effectively treats pediatric meningococcal disease, including meningitis and meningococcemia. This antibiotic offers safe, once-daily dosing and fewer complications like skin lesions compared to penicillin G.
Area of Science:
- Pediatric Infectious Diseases
- Bacterial Meningitis Treatment
- Antimicrobial Therapy
Background:
- Meningococcal disease remains a significant cause of pediatric morbidity and mortality.
- Effective antibiotic treatment is crucial for improving outcomes in children with meningococcal infections.
- Comparing different antibiotic regimens helps optimize therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy and safety of ceftriaxone compared to penicillin G in treating pediatric meningococcal disease.
- To assess clinical recovery time and cerebrospinal fluid (CSF) normalization in treated patients.
- To identify differences in complication rates between the two treatment groups.
Main Methods:
- A comparative study involving pediatric patients diagnosed with meningococcal disease (meningitis or meningococcemia).
- Patients were treated with either ceftriaxone (80-100 mg/kg/day for 4 days) or penicillin G.
- The Damrosch-Stiehm scoring system was used to classify patients with poor prognoses who received antishock therapy.
Main Results:
- Necrotic skin lesions were observed more frequently in the penicillin G group compared to the ceftriaxone group.
- Ceftriaxone demonstrated effectiveness and safety in treating pediatric meningococcal disease.
- The study highlights the advantage of ceftriaxone's once-daily administration schedule.
Conclusions:
- Ceftriaxone is a safe and effective therapeutic option for pediatric meningococcal disease.
- Once-daily administration of ceftriaxone simplifies treatment protocols for pediatric patients.
- Ceftriaxone may be associated with a lower incidence of certain complications, such as necrotic skin lesions.
Abstract:
Twenty children with meningococcal disease (15 with meningococcal meningitis and 5 with meningococcemia without meningitis) were treated with ceftriaxone, 80 to 100 mg/kg/day for 4 days. An additional 22 patients with meningococcal disease (13 with meningitis, 9 with meningococcemia without meningitis) were treated with penicillin G. On the basis of the Damrosch-Stiehm scoring system, 19 patients were classified in the poor prognostic group and were treated with antishock therapy. Clinical recovery time and normalization of CSF were compared in two groups. When the complications were compared, necrotic skin lesions were more frequently seen in the penicillin G group than in those who received ceftriaxone. Ceftriaxone is an effective and safe drug and offers the advantage of once daily administration for treatment of meningococcal disease in pediatric patients.